>>I agree with you to the extent that a survival advantage with a PAP based vaccine is of prime importance now. But,you would care a great deal if Provenge became obsolete within a year or two after launch because it was replaced by a better, more specific and more effective vaccine---in effect the target that we should have been working on and investing in all along.<<
I would, indeed. Do you (does anyone) think GERN has the right stuff and is anywhere near that close?
Market Data 
Markets 
AI
